StockSelector.com
  Research, Select, & Monitor Friday, May 24, 2019 5:32:46 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Revance Therapeutics, Inc.$11.61($.32)(2.68%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Revance Therapeutics, Inc. has an overall rank of 6899 out of 6961 stocks based on 5 positive rankings and 12 negative rankings.

Positive Rankings
Estimated Revenue Growth
Revance Therapeutics rank is 45
Low/Rising MACD
The MACD remains negative, but is rising... suggesting a possible near-term correction. Of companies with a negative, but rising MACD, Revance Therapeutics is ranked 154.
Historic Revenue Growth
Revance Therapeutics rank is 240
Low Put/Call
Revance Therapeutics has a low Put/Call ratio of 0.30 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Revance Therapeutics is ranked 769.
Debt-to-Equity
Revance Therapeutics rank is 1169
Negative Rankings
Negative Past Growth
Revance Therapeutics rank is 48
Negative Net Margin
Revance Therapeutics rank is 100
Price-to-Sales
Revance Therapeutics rank is 101
Down EPS Surprise
Revance Therapeutics missed the consensus earnings estimate when it last reported quarterly earnings.
90 Day Loss
Revance Therapeutics rank is 333
Negative ROE
Revance Therapeutics rank is 369
Negative ROA
Revance Therapeutics rank is 416
Down EPS Surprise
Revance Therapeutics missed the consensus earnings estimate when it last reported quarterly earnings.
Negative Cash Growth
Revance Therapeutics rank is 1014
10 Day Loss
Revance Therapeutics rank is 1376
Price-to-Book
Revance Therapeutics rank is 1483
High vPut/Call
Revance Therapeutics has a high Put/Call ratio of 0.76 on active options expiring within the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Revance Therapeutics is ranked 1817.







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2019 StockSelector.com. All rights reserved.